The pharmacokinetics of paracetamol in adults after cardiac surgery have not been described. Twenty patients were randomized to receive either paracetamol 2 g through a nasogastric tube and as a suppository eight hours later or vice versa. Arterial blood samples were taken at 0.5, one, two, four, six and eight hours after dosing. Each patient was studied for 16 h. There were 16 males and three females. One patient was excluded because of sampling errors. The mean age was 59 (SD 8) years and the mean weight 84 kg (16) .
Paracetamol is routinely used to supplement postoperative analgesia after cardiac surgery. A morphine sparing effect of paracetamol has been demonstrated after gynaecological 1 and orthopaedic surgery 2 . Schug et al 3 have suggested that a combination of acetaminophen (paracetamol) and morphine in orthopaedic and general surgery results in improved quality of pain relief and patient satisfaction compared to the use of morphine alone.
The pharmacokinetics of paracetamol in children after cardiac surgery have been described 4 , but those in adults have not been described. We studied timeconcentration profiles of paracetamol in adults in order to rationalize paracetamol dosing regimens in this population.
METHODS (A) Adult data
Approval from the Regional Health Authority Ethics Committee was obtained. Patients presenting for cardiac bypass surgery were recruited preoperatively into the study over a two-month period. Informed, written consent was given by each patient. Those patients with abnormal preoperative liver function, a history of paracetamol intolerance or allergy, or who had been given paracetamol within 48 hours before surgery were excluded.
A warm cardioplegic solution was used during cardiac bypass surgery. Patients were warmed to a 37.5°C core temperature prior to weaning from bypass. After admission to the postoperative intensive care unit, study participants were randomized to sequentially receive one of the two paracetamol formulations separated by eight hours. The formulations were (a) an oral suspension administered through a nasogastric feeding tube and (b) a triglyceride base suppository. The oral elixir was supplied as a sugar-free, alcohol-free preparation with a standard strength of 250 mg / 5 ml (PSM Holdings Ltd, Auckland, N.Z.). The suppository was a triglyceride base containing suspended paracetamol in a bullet-shaped mould (500 mg) (PSM Holdings Ltd, Auckland, N.Z.). After administration of paracetamol elixir, nasogastric tubes were closed for 30 minutes and then left on free drainage throughout the remaining study period.
Each patient was studied for 16 hours. Arterial blood samples were taken from heparinized radial artery cannulae. These samples were taken at one, two, four, six and eight hours after dosing. An additional sample was taken at 30 minutes after nasogastric suspension administration.
Paracetamol assay
Blood from each patient was separated within hours of collection by centrifugation and stored at -20°C until analysis. Paracetamol concentration was determined by fluorescence polarization immunoassay using the Abbott TDx (Abbott Laboratories, Abbott Park, IL, U.S.A.) according to the manufacturer's instructions. All samples were tested consecutively in batches of 18 on the same day with the same calibration and reagent lot number. Controls (supplied by Baxter Diagnostics, Deerfield, IL, U.S.A.) were run simultaneously and all results were reported to within two decimal points. Sample concentrations were low and the precision was tested by multiple repeat testing with a control of 3.02 mg/l and another of 4.53 mg/l. The average result for the lower concentration was 3.17 mg/l (n=10) and for the higher concentration was 4.53 mg/l (n=10). Hence, despite the rounding error of the test method, it is capable of distinguishing a difference of 1.51 mg/l (P=0.025).
Pharmacokinetics
Population parameter estimates were made using two different regression techniques:
(a) standard two-stage population method. Individual patient parameter estimates were made using non-linear regression with the MK MODEL 5 software package.
(b) non-linear mixed effect model (NONMEM). This model accounts for both between-subject and residual variability (random effects) as well as parameter differences predicted by covariates (fixed effects). The between-subject variability in model parameters was modeled by a proportional variance model, which assumes a log-normal distribution. An additive term characterized the residual unknown variability (Err). This error model assumes that the residual variability is the same order of magnitude over the whole range of measurements. The population mean parameters, between-subject variance and residual variance were estimated using the first order conditional estimate method using ADVAN 2 TRANS 2 of NONMEM V 6 . The covariance between clearance, distribution volume and absorption halftime was incorporated into the model. The quality of fit of the pharmacokinetic model to the data was sought by NONMEM's objective function and by visual examination of plots of observed versus predicted concentrations. Improvement in the objective function (a measure of goodness of fit) was referred to the Chi-squared distribution to assess significance. An objective function change of 3.84 is significant (α=0.05).
A first order input with a lag time, first order elimination, one compartment disposition model was used. The model was parameterized in terms of the absorption half-life (T abs , h), an absorption lag time (T lag , h), volume of distribution (V/F oral , l) and total body clearance (CL/F oral , l/h) after nasogastric administration. Paracetamol was administered either through a nasogastric tube (po) or rectally (pr) and both clearance and distribution volume are confounded by bioavailability. F rectal/oral is the relative bioavailability of the rectal compared to the oral formulation.
Differences between parameter estimates were sought using Student's t test.
Scaling for size
Many functional properties of the body such as metabolic rate have a non-linear relationship to size 7 . Humans have a large weight range. Consequently, parameter values were standardized for a body weight of 70 kg using an allometric power model 7 :
where P i is the parameter in the ith individual, W i is the weight in the ith individual and P std is the parameter in an individual with a weight W std . The PWR parameter was 0.75 for clearance, 1 for distribution volumes and 0.25 for the elimination half-life (T 1/2 ) 8, 9, 10 . T abs was not standardized for size as this parameter is formulation determined.
(B) Paediatric data
Hopkins et al 4 have reported time-concentration profiles after elixir and triglyceride suppositories in 28 febrile neonates, infants and children after cardiac surgery (n=41). Observations (n=359) were taken from time-concentration profiles in Figures 1 to 6 of their paper. Mean ages, weights and doses were taken from that paper's Table 1 . These data were analysed using the same pharmacokinetic model with the NONMEM program. A covariate model was used to describe the effect of age on clearance maturation: CL/F oral =CL/F pop x(1-βxEXP [-AGE in months* Ln(2)/T mat ]) l/h/70 kg where CL/F oral is the clearance in an individual, CL/F pop is the population mean clearance, β is a constant and T mat is the half-time of clearance maturation with age.
RESULTS
Twenty adults were enrolled into the study. One patient (ID 11) was withdrawn because of sampling handling errors. There were 16 males and three females. The mean age was 59 (SD 8) years and the mean weight 84 (SD 16) kg. The surgical procedures were coronary artery bypass grafting (n=17), aortic valve replacement (n=1) and mitral valve replacement (n=1).
A total of 226 observations were collected for analysis. Pharmacokinetic parameter estimates for paracetamol derived using the MKMODEL and NONMEM programs are shown in Tables 1 and 2. Geometric mean population estimates and their coefficients of variation are included in Table 3 . The covariance of the parameters, expressed as the correlation of population parameter variability, is shown in Table 4 .
Time-concentration profiles for each individual, mean of the observations, the predicted mean population profile and mean of the individual fits are shown in Figures 1a and 1b . Prediction for individual fits determined from NONMEM's post hoc step are based on values of the pharmacokinetic parameters for the specific individual, rather than the typical (population) values of these parameters. There was little difference between parameter estimates when paracetamol was first given either orally or rectally. Figures 2a and 2b demonstrate the quality of fit for pharmacokinetic data. There was no difference between the absorption half-life (T abs ) or the absorption lag time (T lag ) of the two formulations.
The covariate age was investigated for its effect on clearance and volume of distribution. Once clearance was standardized for size there was no significant change in the objective function when a scaling parameter for age was placed on clearance (objective function change 1.21) or volume of distribution (objective function change 0 shown in Table 3 . Clearance increased exponentially from neonates to children with a half-time (T mat) of 1.02 months. Clearance in neonates was two-thirds that of older children (β=0.67).
DISCUSSION
Mean peak serum concentrations after either nasogastric or rectal paracetamol 2g were below 10 mg/l in this adult study. A target concentration of 10 mg/l is the steady-state concentration which is reported to reduce temperature to 50% of the maximum possible temperature reduction in febrile children 11, 12 and is also the effect site concentration associated with pain scores less than 6/10 in 90% of children after tonsillectomy 13 . Concentrations associated with analgesia in adults are unknown. If the concentrations associated with analgesia in adults are similar to those in children, then the concentrations reported in this current study are inadequate. Dosing may be infrequent after cardiac surgery, with as few as 3.6 (SD 3.0) doses given over a three day postoperative period 14 . Such infrequent dosing is unable to sustain steady state concentrations. In addition, drug is lost when the practice of free nasogastric drainage is used in the immediate postoperative period.
The absorption half-life for paracetamol following oral administration in healthy subjects ranges from 0.06 to 0.7 h 15 . Paracetamol given by nasogastric tube in this current study was slowly absorbed (T abs 1.59 h, CV 81%) in adults. Gastric emptying is markedly delayed in patients who have undergone cardiac surgery. Goldhill et al 16 report that the time to maximum concentration after oral paracetamol was increased from 14.1 min (SEM 2.1) preoperatively to 225.4 min (SEM 42.3) postoperatively. We report a similar time to maximum concentration of approximately 240 min. This slow absorption due to delayed gastric emptying has considerable impact on the maximum concentrations attained. Higher concentrations could be achieved by either increasing the dose because concentration is directly proportional to dose, or by clamping the nasogastric tube after paracetamol administration. However, even if the nasogastric tube is clamped for two hours, 43% of the dose remains in the stomach at this time when the T abs is 1.49 h and may be lost on venting. Nasogastric paracetamol is a poor method of delivery in adults after cardiac surgery. Absorption was also slow in children after cardiac surgery (T abs 0.36, CV 127%) compared to healthy children (T abs 4.5 min, CV 63%) 13 , but was only one quarter that of adults.
The rectum is an alternative administration route. Rectal absorption of medication is usually slower 618 M. SCHUITMAKER, B. J. ANDERSON ET AL Anaesthesia and Intensive Care, Vol. 27, No. 6, December 1999 than with the oral route, possibly an inherent factor owing to the relatively small surface area in the rectum compared to the duodenum 17 . Absorption is also dependent on the composition of the suppository base, with a lipophilic base having a greater relative bioavailability than a hydrophilic base 18 . Liedtke et al 19 report paracetamol given as 0.5 and 1g suppositories was absorbed slowly with low concentrations that did not reach a maximum for three to four hours, similar to our current findings. The relative bioavailability of rectal compared with oral formulations (F rectal/oral ) has been reported 20 as low as 0.5 12, 20 with a range of 0.24 to 0.98. An increased dose is usually required per return to reach similar concentrations to those attained after oral administration. The adult estimates for clearance (26.4 l/h, CV 29%) and volume of distribution (127 l, CV 28%) were approximately twice those reported for adults (CL/F oral 12-21 l/h; Vd/F oral 56-70 l) 15 , suggestive that the oral bioavailability in this current study is only half that normally seen. The results from the analysis of the paediatric data demonstrate typical CL/F oral , Vd/F oral and F rectal/oral profiles. Our adult estimate of F rectal/oral 0.98 (CV 18%) was probably a consequence of waste from free drainage of nasogastric tubes, which was part of routine postoperative care. Paracetamol has low first pass metabolism with an hepatic extraction ratio of 0.11 to 0.37 in adults 21 , which is unlikely to contribute significantly to differences in relative bioavailability. The impact of the rectal venous drainage pattern with its incomplete return through the liver is questionable, given the degree of rectal venous anastomotic channels and slow absorption times 22 . Other factors such as faecal pH, defaecation and rectal contents vary absorption.
Paracetamol clearance is not dramatically reduced after cardiac surgery. In general paracetamol metabolism seems to be impaired more in jaundiced patients with liver disease than those without jaundice 23 , presumably due to depression of glucuronide conjugation. Although Oochs et al 24 reported a clearance of 14.9 (SEM 1.55) l/h in 12 patients with Class III or IV congestive heart failure compared with a clearance of 19.3 (SEM 0.80) l/h in 12 healthy matched controls, both estimates were within the normal adult population range of 12-21 l/h 15 .
The difference between the NONMEM and MKMODEL estimates reflects the methods by which population parameters are estimated. The outcome of the standard two-stage method is skewed by outlying values more than NONMEM. Both sets of parameters adequately describe time-concentration profiles. However, sampling was truncated in some individuals soon after the peak concentration. NON-MEM predictions have greater merit with respect to such truncated data as predictions are influenced by the population estimates. The MKMODEL estimates are less robust.
Paracetamol serum concentrations in adults could be increased by increasing the dose, but most practitioners are reluctant to prescribe more than 6 g/day because of potential hepatotoxicity 15 . There is evidence of glutathione depletion in adult volunteers given doses as low as 0.5g and 3g paracetamol separated by four to 10 days 25 . The toxic metabolite of paracetamol, N-acetyl-p-benzoquinone imine (NAPQI) is formed by the cytochrome P450s CYP2E1, 1A2 and 3A4 26 . CYP2E1 is the most significant of these. The co-ingestion of therapeutic drugs, foodstuffs or other xenobiotics (e.g. heterocyclic hydrocarbons from tobacco smoke) has potential to induce these enzymes 27 . Alcohol, for example, induces and is a substrate for CYP2E1. If, after enzyme induction by alcohol, paracetamol is ingested without alcohol, then increased formation of NAPQI occurs 26 . Adults who regularly imbibe alcohol may be more susceptible to hepatic damage. It is currently impossible to predict which individuals have an enhanced susceptibility to cellular injury from paracetamol. Analgesia can be modulated with opioids and pyrexia by active cooling. Further, the pharmacodynamic parameter estimates for paracetamol analgesia are large; the CV on the EC 50 has been reported as 94% 13 . Consequently, an increased dose offers little benefit, but does have an increased hepatotoxic risk for many patients.
Paracetamol dosing regimens are determined by potential hepatotoxicity rather than pharmacodynamics. Current dosing regimens in adults after cardiac surgery do not achieve the target concentration 28 of 10 mg/l and the clinical usefulness of paracetamol in the immediate postoperative period is questionable. Although paracetamol tablets may have an adjunct effect with morphine in gynaecological or orthopaedic patients on surgical wards, nasogastric elixir is unlikely to be much use after cardiac surgery in an ICU when gastric emptying is profoundly delayed.
